Indusatumab Biosimilar - Research Grade

Human

GC-C

>1mg/ml

Human IgG1 (E356D/M358L)-kappa

Indusatumab Vedotin Biosimilar - Research Grade (ICH5604V)

https://www.imgt.org/mAb-DB/

ICH3002

P25092

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of indusatumab, an anti-guanylyl cyclase C (GC-C / GUCY2C) human IgG1 antibody originally developed as the targeting arm of an MMAE antibody-drug conjugate for GC-C-expressing gastrointestinal cancers. Supplied for research use only, it is built around the same GC-C target and is not the clinical agent, carries no cytotoxic payload, and is not intended for human or veterinary use. The IgG1-kappa framework carries E356D/M358L allotype substitutions in the Fc. It is offered at research grade (low endotoxin, typically <1 EU/mg; ultra-low <0.5 EU/mg options) and in bulk milligram-to-gram quantities suitable for demanding assays. Typical applications include use as an isotype-matched positive binding control, a reagent for GC-C target-engagement and epitope studies, a benchmark antibody in ADCC or ADC-development workflows, and a tool for characterising GC-C expression on cell lines or tissues. In-vitro and preclinical characterisation contexts are the primary use cases, complementing internally raised antibodies where a defined, reproducible anti-GC-C binder is needed. Guanylyl cyclase C (GC-C), encoded by GUCY2C (UniProt P25092), is a single-pass transmembrane receptor guanylate cyclase. Its extracellular domain binds the endogenous peptides guanylin and uroguanylin, as well as bacterial heat-stable enterotoxins (STa); ligand binding activates the intracellular catalytic domain to convert GTP into cyclic GMP. The resulting cGMP signalling regulates intestinal fluid and electrolyte secretion, epithelial proliferation, and barrier homeostasis. GC-C expression is normally restricted largely to intestinal epithelial cells along the crypt-villus axis, which makes it an attractive tumour-associated target: it is retained and often overexpressed in colorectal, gastric, pancreatic, and esophageal adenocarcinomas, including metastatic lesions. This restricted normal-tissue distribution combined with tumour retention underlies interest in GC-C for targeted therapeutics and diagnostics.

GUCY2C

Detects human GUCY2C

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Indusatumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Indusatumab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Indusatumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Indusatumab that binds human GC-C.